Abstract
SUMMARY: Acute lymphoblastic leukemia (ALL) is early childhood hematological malignancies. In present scenario immunophenotyping became an important tool for subtyping of ALL into B-ALL and TALL. In order to understand the mechanism of development of leukemia it is important to study the cytokine environment of malignant cells. OBJECTIVE: Aim of the present study was to evaluate clinical and hematological features in ALL and correlate serum levels of IL6 and IL-10 expression in ALL patients and their subtypes. MATERIALS & METHODS: A total of 68 ALL cases along with 20 healthy controls were included in the study between periods of 2015 to 2017. About 4 mL blood samples were collected from all cases for immunophenotyping and serum studies. Levels of IL6 and IL10 were determined in all cases by ELISA. RESULT: In the present study immunphenotyping was done in all cases of ALL, which showed 52 cases (76.5%) of B-ALL and 16 cases (23.5%) of T-ALL. T-ALL was mostly found in higher aged children than B-ALL. A male predominance was seen in all cases. No signicant differences in hemoglobin levels and platelet counts were found between T-ALL and B-ALL. A signicantly high percentage of T-ALL cases were having more than 50000 cells per microliter than B-ALL (56.2% vs. 23.1%). Almost similar clinical features were found in both subgroups, only bleeding manifestation was found signicantly higher in T-ALL than B-ALL (31.2% vs.11.5%). Acute lymphoblastic leukemia (ALL) patients were associated with signicantly elevated serum IL6 and IL10 level than the healthy control group. Mean levels of serum IL6 were 167.9±306.46 pg/mL in ALL, and 6.51 ± 2.27 pg/mL in healthy control group. Mean IL10 levels were 70.56±111.48 pg/mL in ALL and 29.39 ± 4.27 pg/mL in control group. There were no signicant differences found in IL-6 and IL-10 serum levels between T-ALL and B-ALL. CONCLUSION: Present study found elevated level of IL-6 and IL-10 in ALL patients which suggest possible role of these cytokines in disease transformation. Detection of IL-6 and IL-10 in newly diagnosed patient may predict disease outcome and possibly poor prognosis in patients
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
